好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Amitriptyline for Acute Mild Traumatic Brain Injury (mTBI)
Neuro Trauma and Critical Care
P3 - Poster Session 3 (5:00 PM-6:00 PM)
3-001

To investigate the utility of amitriptyline in expediting recovery and symptom relief in acute mTBI. 

Pharmacological treatment of acute mTBI symptoms has been elusive. Unaddressed symptoms, especially headache, may complicate recovery and have lingering effects if not aborted. Amitriptyline, a tricyclic antidepressant, is used for off-label purposes 81% of the time, including migraine prophylaxis. The research is inconclusive on the use of amitriptyline to address headache in mTBI, however a number of studies reveal beneficial effects. We have observed improvement of multiple symptoms in patients treated with amitriptyline in our clinic. 

Retrospective review of 383 acute mTBI patients (mean age 22.4±13.3; 56% female) seen within 21 days of injury. Concussion symptoms were assessed using the Post-Concussion Symptom Scale. Statistical methods for comparing characteristics between patients on amitriptyline and those not on the medication involved using independent t-tests for continuous variables and chi-square tests for categorical variables. 

Patients prescribed amitriptyline (n=250) recovered within an average of 39.7±32.7 days with a recovery rate of 100%. Within the subset of concussion patients with a history of depression (n=53), those who were prescribed amitriptyline reported a symptom score that rapidly decreased from the first week of amitriptyline use to week three. By week three, symptom scores for this patient subgroup remained below 5 out of 132 on the scale, with mean scores approximating zero by week six. 

Data from our clinic reveals that patients presenting with more severe symptoms and a history of comorbidities considered risk factors for prolonged recovery were prescribed amitriptyline, which was beneficial in achieving full recovery defined as complete resolution of symptoms. Our results suggest that amitriptyline is a viable pharmacological option in treating mTBI symptoms, and may prevent lingering effects in a patient subset vulnerable to prolonged recovery, those with a history of depression. 

Authors/Disclosures
Ava Panetto
PRESENTER
Ms. Panetto has nothing to disclose.
Guzide Ayse Erdemir Miss Erdemir has nothing to disclose.
Niluckshi Pitigala, NP Mrs. Pitigala has nothing to disclose.
Joseph T Nguyen Joseph T Nguyen has nothing to disclose.
Teena Shetty, MD, FAAN (Hospital for Special Surgery) Dr. Shetty has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for mTBI, Inc. The institution of Dr. Shetty has received research support from Marker AG. The institution of Dr. Shetty has received research support from GE-NFL.